# IDEAYA Biosciences share price today (IDEAYA Biosciences, Inc., IDYA)

> IDEAYA Biosciences, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. IDYA · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/idya

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $30.65 (+1.4% in a year)
- Revenue (Jun 2026): ₹0.0 B
- Profit (Jun 2026), incl. one-off: −₹0.1 B (one-off item, see below)
- Operating margin: −1,380.7%

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the IDEAYA Biosciences share price today? IDEAYA Biosciences, Inc.'s share price was $30.65 at the close on 5 November 2026. It has been moving sideways for 2 weeks. That is 9.7% below its average price over the last 200 trading days. In the last 52 weeks it traded between $28 and $40, and at that close it sat 21% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 7 weeks running. Over the last 7.4 years the share price moved +172% while the S&P 500 moved +159%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 18 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does IDEAYA Biosciences pay? IDEAYA Biosciences, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is IDEAYA Biosciences on? IDEAYA Biosciences is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is IDEAYA Biosciences profitable? IDEAYA Biosciences, Inc. posted a net loss of ₹0.1 B in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY25 year was a loss of ₹0.1 B. That loss is 1,269.6% of the quarter's revenue. The same quarter a year earlier lost ₹0.1 B. 10 of the last 12 reported quarters were loss-making. Read this profit with care: at −₹0.1 B it is bigger than the quarter's whole revenue of ₹0.0 B. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −1,380.7% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## How much revenue does IDEAYA Biosciences make, and is it growing? IDEAYA Biosciences, Inc. reported ₹0.0 B of revenue in the Jun 2026 quarter. Over 4 years it has grown 67.3% a year on average. The last full year, FY25, came in at ₹0.2 B. The last four reported quarters add to ₹0.2 B. FY25 revenue was ₹0.2 B, +3,024.4% on the year before. Recent pace: the last four quarters grew +55.4% on average, against 67.3% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +940.4%, against +122.1% a year over the last 8 quarters (accelerating). This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## How much of its sales does IDEAYA Biosciences keep? IDEAYA Biosciences, Inc.'s operating margin was −1,380.7% in the Jun 2026 quarter. Over the last four quarters it has moved +678.4 percentage points. Across 5 years it has been between −4,671.1% and −72.8%. The latest quarter is within that range. Why the margin moved: operating margin changed +678.4 percentage points on the year while gross margin changed +775.4 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is IDEAYA Biosciences' profit turning into cash? IDEAYA Biosciences, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used ₹0.1 B of cash, against −₹0.1 B of profit. After ₹0.0 B of spending on assets, free cash was −₹0.1 B: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: it spends almost nothing on new assets, so the cash goes on running the business. The next section shows the spending figures. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## Where does IDEAYA Biosciences' cash go? IDEAYA Biosciences, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent ₹0.0 B on assets over the last 3 years. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: ₹0.0 B over the last 3 years. In short: almost nothing is being spent on new assets, so the cash goes on running the business. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## What is IDEAYA Biosciences' P/E ratio, and how does it compare with its own history? IDEAYA Biosciences, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. The P/E comes back here once profit turns positive. ## Is the IDEAYA Biosciences business getting better or worse? IDEAYA Biosciences, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 9 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does IDEAYA Biosciences earn on its capital? IDEAYA Biosciences, Inc. earned a ROE of −11% in FY25. That is up from a low of −26% in FY24. Its return on capital used (ROIC) is left out: on sales this small it reads −26%, a number that says nothing useful about the business. It comes from a −52.0% net margin and 0.20× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −52.0% net margin × 0.20× asset turnover × 1.08× leverage (assets divided by equity) ≈ −11.2% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. ## Does IDEAYA Biosciences have too much debt? IDEAYA Biosciences, Inc. has total debt of ₹0.0 B against shareholder equity of ₹1.2 B as of Jun 2026, so its debt is 0.02× its equity, which is very little. Year by year, that ratio went from 0.02 in FY21 to 0.03 in FY25. So the returns on this page come from the business, not from borrowed money. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## What is the IDEAYA Biosciences shareholding pattern? 10.0% of IDEAYA Biosciences, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 9.9 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is IDEAYA Biosciences from balance-sheet trouble? For IDEAYA Biosciences, Inc., the Z-score is 12.97. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 12.97 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does IDEAYA Biosciences rank in its industry? There is no score against its industry: IDEAYA Biosciences, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is IDEAYA Biosciences compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to IDEAYA Biosciences in size? IDEAYA Biosciences is the 60th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Tarsus Pharmaceuticals, Inc., Viridian Therapeutics, Inc. and Denali Therapeutics Inc. Just below it: ADMA Biologics, Inc., Zai Lab and AtaiBeckley Inc. ### Biotechnology companies close in size

1. [Tarsus Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/tars) $3.3 billion
2. [Viridian Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/vrdn) $3.2 billion
3. [Denali Therapeutics Inc.](https://www.sectoralpha.in/us/stocks/dnli) $3.2 billion
4. IDEAYA Biosciences, Inc. $3 billion
5. [ADMA Biologics, Inc.](https://www.sectoralpha.in/us/stocks/adma) $2.9 billion
6. [Zai Lab Limited](https://www.sectoralpha.in/us/stocks/zlab) $2.8 billion
7. [AtaiBeckley Inc.](https://www.sectoralpha.in/us/stocks/atai) $2.7 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [SkyWest, Inc.](https://www.sectoralpha.in/us/stocks/skyw) $3.1 billion · Airlines
2. [OneSpaWorld Holdings Limited](https://www.sectoralpha.in/us/stocks/osw) $3.1 billion · Leisure
3. IDEAYA Biosciences, Inc. $3.1 billion
4. [MINISO Group Holding Limited](https://www.sectoralpha.in/us/stocks/mnso) $3.1 billion · Specialty Retail
5. [Hilton Grand Vacations Inc.](https://www.sectoralpha.in/us/stocks/hgv) $3.1 billion · Resorts & Casinos

## What else do people ask about IDEAYA Biosciences? ### What is IDEAYA Biosciences's stock price today? IDEAYA Biosciences, Inc.'s stock price is $30.65, +1.4% over the past year. The whole company is worth $3.0 B on the market. In the last 52 weeks it traded between $28 to $40; today it is 21% of the way up from the low, 9.7% below its 200-day average (as of 5 November 2026). ### What were IDEAYA Biosciences's latest quarterly results? IDEAYA Biosciences, Inc. reported revenue of ₹0.0 B and a net loss of ₹0.1 B for the Jun 2026 quarter. The operating margin was −1,380.7% (as of 5 November 2026). ### What is IDEAYA Biosciences's market cap? IDEAYA Biosciences, Inc.'s market capitalisation is $3.0 B at a stock price of $30.65. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is IDEAYA Biosciences performing? IDEAYA Biosciences, Inc.'s share price has been moving sideways for 2 weeks. Over the past 13 weeks it has done worse than the S&P 500, for 7 weeks running. This describes what the data did, not a rating (as of 5 November 2026). ### Will IDEAYA Biosciences's stock price go up? This page does not forecast IDEAYA Biosciences, Inc.'s stock price. What it shows instead: the stock price is $30.65, and it has been moving sideways for 2 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 5 November 2026). ### Where is IDEAYA Biosciences in its business cycle? IDEAYA Biosciences, Inc.'s FY25 operating margin was −72.8%, against a 5-year range of −4,671.1% to −72.8%: the middle of its own range, neither a peak nor a low. The latest quarter was −1,380.7%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 5 November 2026). ### What could break the IDEAYA Biosciences story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is IDEAYA Biosciences a stock worth studying right now? What the numbers show: IDEAYA Biosciences, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.